EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer

Najat Bouchmaa iD, Reda Ben Mrid, Youssef Bouargalne, Sana Ajouaoi, Francesco Cacciola iD, Rachid El Fatimy, Mohamed Nhiri, Abdelmajid Zyad

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0272781 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Najat Bouchmaa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science and Technology, Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immuno-Pharmacology, Sultan Moulay Sl…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lalla Salma Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Women’s breast cancer is one of the most significant healthcare issues for the human race that demands a proactive strategy for a cure. In this study, the cytotoxic activity (MTT assay) of two natural steroidal compounds, protodioscin and dioscin, against two major subtypes of human breast cancer estrogen receptor-positive (ER-positive)/MCF-7 and triple-negative breast cancer (TNBC)/MDA-MB-468), was assessed. The clonogenic capacity was evaluated using the clonogenic assay. Oxidative stress was determined by measuring the formation of malondialdehyde and H 2 O 2 and the assessment of total antioxidant enzyme activities (SOD, GPx, GR, and TrxR). Protodioscin and dioscin were highly cytotoxic against the tested cell lines (1.53 μM

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsTriple Negative Breast NeoplasmsFemaleHumansAntioxidantsCell Line, TumorCell ProliferationHydrogen PeroxideLeukocytes, MononuclearEndoplasmic ReticulumDiosgeninSaponins

Substanzen

Antineoplastic AgentsAntioxidantsHydrogen PeroxidedioscinDiosgeninprotodioscinSaponins

Autor:innen und Institutionen

  • Faculty of Science and Technology, Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immuno-Pharmacology, Sultan Moulay Slimane University, Beni-Mellal, Morocco.
  • Institute of Medical and Biological Sciences, Mohammed VI Polytechnic University (UM6P), Ben-Guerir, Morocco.
  • Faculty of Science and Technology, Laboratory of Biochemistry and Molecular Genetics, Abdelmalek Essaadi University, Tangier, Morocco.
  • Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.

ORCID-Profile: Najat Bouchmaa, Francesco Cacciola

Förderung

  • Lalla Salma Foundation

Zitieren

APA

Bouchmaa, N., Ben Mrid, R., Bouargalne, Y., Ajouaoi, S., Cacciola, F., El Fatimy, R., Nhiri, M., & Zyad, A. (2023). In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0272781

Vancouver

Bouchmaa N, Ben Mrid R, Bouargalne Y, Ajouaoi S, Cacciola F, El Fatimy R, et al. In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer. PLOS ONE. 2023. doi:10.1371/journal.pone.0272781

BibTeX
@article{Bouchmaa2023,
  author = {Bouchmaa, Najat and Ben Mrid, Reda and Bouargalne, Youssef and Ajouaoi, Sana and Cacciola, Francesco and El Fatimy, Rachid and Nhiri, Mohamed and Zyad, Abdelmajid},
  title = {In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0272781}
}
Kostenlos starten →